Utility of sulfobutyl ether β-Cyclodextrin inclusion complexes in drug delivery

A review

O. Das, V. M. Ghate, S. A. Lewis

Research output: Contribution to journalReview article

Abstract

The potential of β-cyclodextrins as a pharmaceutical aid has been established through several decades of research. However, some β-cyclodextrins are reported to be toxic causing deleterious effects on long term usage. In the recent past, sulfobutyl ether β-cyclodextrin, a modified β-cyclodextrin has captured interest as a comparatively safer and effective β-cyclodextrin for increasing the solubility and the bioavailability of biopharmaceutical classification system class II drugs. Sulfobutyl ether β-cyclodextrin has demonstrated immense potential in addressing solubility and stability issues associated with formulation of drugs. Till date no comprehensive report on their utility in drug development has been published. Hence, this review focusses on the structure, properties, preparation techniques and applications of sulfobutyl ether β-cyclodextrin inclusion complexes. Investigation of the feasibility of forming stable inclusion complexes of sulfobutyl ether β-cyclodextrin and various drugs as guest molecules using molecular modelling techniques have been elaborated in the review. Incorporation of sulfobutyl ether β-cyclodextrin complexes into novel drug delivery systems (liposomes and nanoformulations) have been summarized along with various methods of preparation and the clinical safety. Molecular modelling approach discussed in this review, coupled with wet-lab validation of the complexes, will enable a faster transit of the delivery systems into the clinical setting.

Original languageEnglish
Pages (from-to)589-600
Number of pages12
JournalIndian Journal of Pharmaceutical Sciences
Volume81
Issue number4
Publication statusPublished - 01-01-2019

Fingerprint

Cyclodextrins
Ether
Pharmaceutical Preparations
Solubility
Pharmaceutic Aids
Drug Compounding
Poisons
Drug Delivery Systems
Liposomes
Biological Availability
Safety

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

@article{b9a09dc0b3834878b6d32610e3021d27,
title = "Utility of sulfobutyl ether β-Cyclodextrin inclusion complexes in drug delivery: A review",
abstract = "The potential of β-cyclodextrins as a pharmaceutical aid has been established through several decades of research. However, some β-cyclodextrins are reported to be toxic causing deleterious effects on long term usage. In the recent past, sulfobutyl ether β-cyclodextrin, a modified β-cyclodextrin has captured interest as a comparatively safer and effective β-cyclodextrin for increasing the solubility and the bioavailability of biopharmaceutical classification system class II drugs. Sulfobutyl ether β-cyclodextrin has demonstrated immense potential in addressing solubility and stability issues associated with formulation of drugs. Till date no comprehensive report on their utility in drug development has been published. Hence, this review focusses on the structure, properties, preparation techniques and applications of sulfobutyl ether β-cyclodextrin inclusion complexes. Investigation of the feasibility of forming stable inclusion complexes of sulfobutyl ether β-cyclodextrin and various drugs as guest molecules using molecular modelling techniques have been elaborated in the review. Incorporation of sulfobutyl ether β-cyclodextrin complexes into novel drug delivery systems (liposomes and nanoformulations) have been summarized along with various methods of preparation and the clinical safety. Molecular modelling approach discussed in this review, coupled with wet-lab validation of the complexes, will enable a faster transit of the delivery systems into the clinical setting.",
author = "O. Das and Ghate, {V. M.} and Lewis, {S. A.}",
year = "2019",
month = "1",
day = "1",
language = "English",
volume = "81",
pages = "589--600",
journal = "Indian Journal of Pharmaceutical Sciences",
issn = "0250-474X",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "4",

}

Utility of sulfobutyl ether β-Cyclodextrin inclusion complexes in drug delivery : A review. / Das, O.; Ghate, V. M.; Lewis, S. A.

In: Indian Journal of Pharmaceutical Sciences, Vol. 81, No. 4, 01.01.2019, p. 589-600.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Utility of sulfobutyl ether β-Cyclodextrin inclusion complexes in drug delivery

T2 - A review

AU - Das, O.

AU - Ghate, V. M.

AU - Lewis, S. A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The potential of β-cyclodextrins as a pharmaceutical aid has been established through several decades of research. However, some β-cyclodextrins are reported to be toxic causing deleterious effects on long term usage. In the recent past, sulfobutyl ether β-cyclodextrin, a modified β-cyclodextrin has captured interest as a comparatively safer and effective β-cyclodextrin for increasing the solubility and the bioavailability of biopharmaceutical classification system class II drugs. Sulfobutyl ether β-cyclodextrin has demonstrated immense potential in addressing solubility and stability issues associated with formulation of drugs. Till date no comprehensive report on their utility in drug development has been published. Hence, this review focusses on the structure, properties, preparation techniques and applications of sulfobutyl ether β-cyclodextrin inclusion complexes. Investigation of the feasibility of forming stable inclusion complexes of sulfobutyl ether β-cyclodextrin and various drugs as guest molecules using molecular modelling techniques have been elaborated in the review. Incorporation of sulfobutyl ether β-cyclodextrin complexes into novel drug delivery systems (liposomes and nanoformulations) have been summarized along with various methods of preparation and the clinical safety. Molecular modelling approach discussed in this review, coupled with wet-lab validation of the complexes, will enable a faster transit of the delivery systems into the clinical setting.

AB - The potential of β-cyclodextrins as a pharmaceutical aid has been established through several decades of research. However, some β-cyclodextrins are reported to be toxic causing deleterious effects on long term usage. In the recent past, sulfobutyl ether β-cyclodextrin, a modified β-cyclodextrin has captured interest as a comparatively safer and effective β-cyclodextrin for increasing the solubility and the bioavailability of biopharmaceutical classification system class II drugs. Sulfobutyl ether β-cyclodextrin has demonstrated immense potential in addressing solubility and stability issues associated with formulation of drugs. Till date no comprehensive report on their utility in drug development has been published. Hence, this review focusses on the structure, properties, preparation techniques and applications of sulfobutyl ether β-cyclodextrin inclusion complexes. Investigation of the feasibility of forming stable inclusion complexes of sulfobutyl ether β-cyclodextrin and various drugs as guest molecules using molecular modelling techniques have been elaborated in the review. Incorporation of sulfobutyl ether β-cyclodextrin complexes into novel drug delivery systems (liposomes and nanoformulations) have been summarized along with various methods of preparation and the clinical safety. Molecular modelling approach discussed in this review, coupled with wet-lab validation of the complexes, will enable a faster transit of the delivery systems into the clinical setting.

UR - http://www.scopus.com/inward/record.url?scp=85072250760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072250760&partnerID=8YFLogxK

M3 - Review article

VL - 81

SP - 589

EP - 600

JO - Indian Journal of Pharmaceutical Sciences

JF - Indian Journal of Pharmaceutical Sciences

SN - 0250-474X

IS - 4

ER -